Alkem Laboratories will conduct an in-person analyst and institutional investor meeting with HDFC Mutual Fund in Mumbai on October 7, 2026. The engagement is scheduled as a one-on-one session.

The company filed an intimation with BSE Limited and National Stock Exchange of India Limited regarding the schedule of this meeting. The disclosure was made under the relevant provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Meeting Details

The specific details of the scheduled interaction are outlined below:

Alkem Laboratories noted that the schedule of the aforementioned meeting is subject to change due to exigencies on the part of the investor or the company. The communication was signed by Divya Mewani, Vice President – Legal & Deputy Company Secretary.

Alkem Laboratories launched NeuCeno (cenobamate) on September 16, 2026, for treating partial-onset seizures in adult patients. This marks the first launch of cenobamate in India.

Product overview

NeuCeno is an anti-seizure medication (ASM) indicated for adults with partial-onset seizures. It is designed as a once daily oral therapy to support patient adherence.

The drug acts through a unique dual mechanism of action:

• Selectively inhibits the persistent sodium current that drives repetitive neuronal firing
• Enhances the brain's natural inhibitory signaling via positive modulation of GABA-A receptors

In randomized clinical studies involving adults with uncontrolled focal seizures on existing medications, adjunctive cenobamate produced up to 78% reduction in seizure frequency. Up to 30% of patients achieved seizure freedom during the maintenance phase.

Launch details

NeuCeno is available in six tablet strengths: 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg.

Epilepsy affects an estimated 9.4 million people in India. Despite multiple available anti-seizure medications, a significant proportion of patients continue to experience uncontrolled seizures, impacting their independence and quality of life.

Management comment

Sandeep Singh, Managing Director, Alkem Laboratories Limited, stated that cenobamate has the potential to transform treatment outcomes for epilepsy management. He noted that patients deserve access to advanced treatment options addressing unmet medical needs.

The launch expands Alkem's neurology portfolio, adding to its existing dominance in anti-infectives, gastrointestinal, pain management drugs, and supplements.